Mild to moderate COVID-19 COVID-19, favipiravir, SARS-CoV-2, treatment
Conditions
Interventions
The patients who received favipiravir is 3600 mg on the first day as a loading dose, then the maintenance dose of favipiravir is 1600 mg/day. In obese patients, favipiravir is 4800 mg on the first da
Treatment,Treatment
Favipiravir treated group,Standard treatment group
Sponsors
Chulabhorn Royal Academy
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed SARS-COV-2 infected cases by Reverse Transcriptase-Polymerase Chain Reaction or Rapid antigen testing from respiratory specimens which were treated with outpatients, home isolation, or lived in quarantine facilities 2. Mild to moderate illness 3. Participants accept informed consent
Exclusion criteria
Exclusion criteria: 1. Age less than 20-year-old 2. Who lives in long-term facilities, or prison 3. Patients who need hospitalization on the initial day 3. Severe or critical COVID-19 3.1 respiratory rate > 30 / min 3.2 SpO2 less than 95% 3.3 Patients who need oxygen therapy 3.4 Respiratory failure 3.5 Shock or BP<90/60 3.6 Multi-organ failure 3.7 WHO clinical progression scale more than or equal to 3 4. Pregnant or breast-feeding conditions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of non-deteriorated patients Day 5 WHO clinical progression scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of non-deteriorated patients Day 14 WHO clinical progression scale,Proportion of clinical imrovement Day 5, 14 Overall symptoms,Proportion of each symptom improvement Day 1- 14 VAS score,Hospitalization 14 days Numbers,Oxygen supplemental 14 days Number,Days of symptoms resolution 14 days Day of resolution,Adverse events 14 days possible adverse events | — |
Countries
Thailand
Contacts
Public ContactTaweegrit Siripongboonsitti
Chulabhorn Hospital, Chulabhorn Royal Academy
Outcome results
None listed